Efficacy and Safety of Fremanezumab for Episodic Cluster Headache
- Study Title
- A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)
- Teva Identifier
- TV48125-CNS-30056 | 2016-003278-42
- ClinicalTrials.gov Identifier
- NCT02945046
- Study Status
- Terminated
- Trial Condition(s)
- Episodic Cluster Headache
- Interventions
- Drug: Fremanezumab | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- January 19, 2017 - May 13, 2019
- Phase
- Phase 3
